l-LV (dl-LV)

DRUG2 trials

Sponsors

Epidemiological and Clinical Research Information Network, Sun Yat-sen University

Conditions

Colorectal NeoplasmsDigestive System NeoplasmsGastrointestinal NeoplasmsIntestinal NeoplasmsNeoplasm Metastasis

Phase 3

A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC

CompletedNCT01996306

Epidemiological and Clinical Research Information NetworkColorectal Neoplasms, Digestive System Neoplasms, Gastrointestinal Neoplasms +2

Start: 2013-12-02End: 2018-06-30Updated: 2019-01-08

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

RecruitingNCT03303495

Sun Yat-sen UniversityColorectal Neoplasms, Digestive System Neoplasms, Gastrointestinal Neoplasms +2

Start: 2011-11-14End: 2026-12-31Target: 280Updated: 2026-06-05

Related Papers

Differential association of proton pump inhibitors with efficacy of capecitabine and 5-fluorouracil in metastatic colorectal cancer: A post-hoc analysis from AXEPT phase III trial.

Journal of Clinical Oncology2020-05-20

Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.

Journal of Clinical Oncology2019-01-29

Global phase III trial of comparing mXELIRI+BV vs FOLFIRI+Bmab for 2nd line mCRC (AXEPT) Japanese population analysis

Annals of Oncology2018-10-011 citations

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

2018-03-16107 citations

A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).

Journal of Clinical Oncology2017-02-013 citations

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

Chinese Journal of Cancer2016-12-0115 citations

A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

Journal of Clinical Oncology2016-02-013 citations